Heard on the Street: Novartis's deal to acquire Medicines Co. is a calculated risk worth taking
By Charley Grant Nov. 25, 2019 1:23 pm ET There is a method to the madness of Novartis NVS 0.91% chief executive Vas Narasimhan’s deal strategy.
The spending spree does come with obvious risks, yet Novartis shares rallied Monday, because the price tag for Medicines looks better in the proper context. High cholesterol is a leading cause of heart disease, and obesity is on the rise across the developed world. The drug industry has spent more heavily in categories like oncology or rare diseases than on cardiovascular illnesses. New commercial opportunities are therefore scarce.
Pricing the drug carefully to limit insurer pushback will be important, but there is blockbuster potential. Analysts expect nearly $1 billion in sales for inclisiran by 2023, according to FactSet. That market could significantly expand in coming years. A long-term study showing patient health outcomes on the drug is due in 2024 which could expand the pool of eligible patients.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Grigorishin making a splash with his ISL revolutionUkrainian energy tycoon Konstantin Grigorishin is leading a revolution in the po...
Baca lebih lajut »
Dell CFO Tom Sweet discusses Dell's big bet in buying EMC and VMware - Business InsiderThe CFO of Dell explains how a 5-minute call with Michael Dell put him in the position of navigating the company through a $67 billion mega-merger and a public offering
Baca lebih lajut »
'Tuesday Afternoon Impeachment' Is as Big as 'Monday Night Football'On the third day that impeachment hearings blanketed American televisions, from morning talk shows to late-night monologues, Rep. Devin Nunes came out with a public service announcement."TV ratings are way down, way down," Nunes, the ranking Republican on the House Intelligence Committee, declared
Baca lebih lajut »